Back to search

Article

Aspirin Synergizes with Regorafenib to Reduce Growth of Colorectal Cancer

2022-02-11

Abstract excerpt

<h4>Purpose</h4> Regorafenib is a multi-kinase inhibitor approved for refractory metastatic colorectal cancer. Previous studies have suggested that combining kinase inhibitors with aspirin may improve patient outcomes. We aimed to determine the effects of aspirin and regorafenib combination treatment in preclinical models of colorectal cancer. <h4>Experimental Design</h4> SW480, RKO and LIM1215 colorectal cancer...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
84f96673-c2e8-56f3-a69a-afb8eda0081d
DOI
10.1101/2022.02.11.480021
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Aspirin Synergizes with Regorafenib to Reduce Growth of Colorectal CancerDOI 10.1101/2022.02.11.480021
KRAS exon 2 mutations influence activity of regorafenib in an SW48-based disease model of colorectal cancer.Semantic proximity
Regorafenib synergizes with TAS102 against multiple gastrointestinal cancers and overcomes cancer stemness, trifluridine-induced angiogenesis, ERK1/2 and STAT3 signaling regardless of KRAS or BRAF mutational status.Semantic proximity
Selective Eradication of Colon Cancer Cells Harboring PI3K and/or MAPK Pathway Mutations in 3D Culture by Combined PI3K/AKT/mTOR Pathway and MEK Inhibition.Semantic proximity
[Regorafenib in patients with metastatic colorectal cancer: a review and an update].Semantic proximity
Andrographis overcomes 5-fluorouracil-associated chemoresistance through inhibition of DKK1 in colorectal cancerSemantic proximity
Aspirin-Induced Chemoprevention and Response Kinetics Are Enhanced by PIK3CA Mutations in Colorectal Cancer Cells.Semantic proximity
Cellular mechanisms of acquired drug resistance against regorafenib in colon cancer cellsSemantic proximity
Regorafenib Therapy as a Third-Line Treatment for Metastatic Colorectal Cancer: A Single Center Long Term ExperienceSemantic proximity
High Throughput Screening Identifies Small Molecules that Synergize with MRTX1133 Against Acquired Resistant KRAS <sup>G12D</sup> Mutated CRCSemantic proximity
Preclinical Drug Testing of the CDK 4/6 Inhibitor Palbociclib in Combination With a PI3K or MEK Inhibitor in Colorectal Cancer Cell LinesSemantic proximity
Additive Cytotoxic and Colony-Formation Inhibitory Effects of Aspirin and Metformin on PI3KCA-Mutant Colorectal Cancer Cells.Semantic proximity
The rational modulation of autophagy sensitizes colorectal cancer cells to 5-fluouracil and OxaliplatinSemantic proximity
Select a neighboring publication to make it the new centre.